Why the study?
Studies investigating the therapeutic potential of growth hormone receptor antagonism in cancer and diabetic microvascular complications have been limited, likely due to difficulty accessing in vivo therapeutic tools.
Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Review of GH antagonism strategies; leaves open their cardiovascular applications in diabetes pending trials.
Lu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: